Protalix BioTherapeutics
PLX
PLX
26 hedge funds and large institutions have $4.87M invested in Protalix BioTherapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more first-time investments, than exits
New positions opened: | Existing positions closed:
0.09% less ownership
Funds ownership: 7.13% → 7.04% (-0.09%)
4% less funds holding
Funds holding: 27 → 26 (-1)
Holders
26
Holding in Top 10
–
Calls
$1.41M
Puts
$125K
Top Buyers
| 1 | +$147K | |
| 2 | +$90.1K | |
| 3 | +$68K | |
| 4 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$49K |
| 5 |
Jane Street
New York
|
+$18.8K |
Top Sellers
| 1 | -$231K | |
| 2 | -$23K | |
| 3 | -$15K | |
| 4 |
ACA
Aptus Capital Advisors
Fairhope,
Alabama
|
-$15K |
| 5 |
Two Sigma Advisers
New York
|
-$6.44K |